



**FIG. 1**

09776780.1020601




*FIG. 2A*




*FIG. 2B*

09776781-020501



**FIG. 2C**



**FIG. 2D**

05275781-020601




FIG. 3A




FIG. 3B




FIG. 3C

T09020: T8292250




FIG. 4C

FIG. 4B

FIG. 4A

109020 \* 182922




FIG. 4D




FIG. 4E






FIG. 4F


06776751-020501



**FIG. 5A**



**FIG. 5B**




IL-2R GAMMA CHAIN

IL-2R GAMMA CHAIN

**FIG. 5C**

INTERLEUKINE-2 RECEPTOR



*FIG. 6A*

09776781 - 020561

TO 9020 \* T8Z9Z5E

1L-2 AND 1P 130 SEQUENCE (  $\alpha$ -HELICES ARE BOXED)




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C

199020 "T3922450




FIG. 8A

FIG. 8B

FIG. 8C





FIG. 8D



TDS020-TB94Z60




FIG. 9A

FIG. 9B

FIG. 9C

109020-TBZ-92450






FIG. 9D  
FIG. 9E

$\triangle$  P130 + mAb A41 (Anti-IL-2R $\beta$ )  
 $\blacksquare$  IL-2 + mAb A41  
 $\square$  IL-9 + mAb A41


			% HELIX	MAIN MOLECULAR SPECIES	ACTIVITY
1	10	20	30	(CIRCULAR DICHROISM)	
				TETRAMER (4M-8M, Kd=30-100μM)	+++
1		30	50% (150 @ 30μM) 35% (4μM)	/OCTAMER	
				DIMER (1M-2M, Kd=0.2μM)	++
10		30	22% (150 @ 30μM)	/TETRAMER (2M-4M, Kd=100μM)	
				-	
1		22	<2%		
				DIMER (1M-2M, Kd=50μM) (2M-4M, Kd=1.4mM)	-
1		10	0%		
				DIMER (1M-2M, Kd=113μM)	-
5		15	0%		
				MONOMER	ND
10		20			
				MONOMER	+
20		20	<5%		

FIG. 10



IP130

*FIG. 11A*




IP130

*FIG. 11B*

04776781 • 020601

T090200 "T22Z9Z60

BLOT 4G10 (ANTI  
PHOSPHOTYROSINE)





NO STIMULATION  
IL-2 (10 MIN)  
IP 130(1 MIN)  
IP 130(2 MIN)  
IP 130(5 MIN)  
IP 130(10 MIN)  
IP 130(15 MIN)

FIG.12 A

109020713232760

BLOT ANTI SHC








FIG. 14

MODEL OF TRANSDUCTION PATHWAY INDUCED BY gp130

IL-2 RECEPTOR AND ITS MAJOR SIGNAL TRANSDUCTION PATHWAY

NK CELLS ( $CD56^+$ ) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION  
 (SYNTERGY WITH IL-2)

TREATMENT	J31	J32	J33
IL-2 50 nM	14	12	14
IP130 60 $\mu$ M	0	17	$\leq 5$
IP130 120 $\mu$ M	0	14	<5
IL-2 50 nM + IP130 60 $\mu$ M	26	21	7
IL-2 50 nM + IP130 120 $\mu$ M	28	28	28

**FIG. 15**

TOSOZO · TOSOZO · TOSOZO · TOSOZO · TOSOZO

Y09020 "T2Z9Z250






FIG. 16A

FIG. 16B

*FIG. 16D*



*FIG. 16C*



109020 \* T8/92/250




FIG. 16F

FIG. 16E

T09020 " T8Z9Z60




FIGURE 17




FIGURE 18




FIGURE 19